watching it as well - summary of session 3 (MSCs for patients with COVID-19)
Josh Hare - MSCs for COVID under EAP
14 patients (9 on ECMO) - 78% survival vs 55% in control group), suggested function of MSCs for COVID beyond just the lungs (heart mentioned)
Joan Kurtzberg
Looking at MIS-C using MSCs (not Mesoblast cells) - no data as yet but linked the mesoblast data demonstrating reduction of inflammation, safety over 10 yrs across 4000 doses delivered to kids (infants to 10) as a contributing factor as to why she thinks it will work. Phase 1 will be 4 doses @ 2millions cells/kg
Wenchun Qu - meta analysis - 5 comparative studies with control/treatment groups (179 patients total). 4 studies showed decreased mortality, 1 increased. Overall mortality was 25% for treated cf 43% controls ie 75% survival vs 57% survival)
From the data - Hare, Qu and MSB survivals are comparable (78%, 75% and 83% respectively) - 'control' survivals were similar (55%, 57% and IIRC, we are expecting around 50% survival for the current MSB phase 3?)
- Forums
- ASX - By Stock
- MSB
- MESO action tonight
MESO action tonight, page-2499
-
-
- There are more pages in this discussion • 661 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 2000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280000 | 1.065 |
5 | 149799 | 1.060 |
9 | 124023 | 1.055 |
14 | 191984 | 1.050 |
8 | 134232 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 2000 | 1 |
1.075 | 19000 | 2 |
1.080 | 48905 | 3 |
1.085 | 28905 | 1 |
1.090 | 61845 | 5 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |